Delivers Illumina's flagship oncology products
on its most powerful sequencers to enable comprehensive genomic
profiling at greater scale and at lower overall costs for
customers
SAN
DIEGO, Aug. 5, 2024 /PRNewswire/ -- Illumina
Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and
array-based technologies, today announced it has expanded its
oncology menu for NovaSeq™ X Series customers. The company began
offering the newly verified high-throughput version of TruSight™
Oncology 500 (TSO 500 HT), and the latest version of its
distributed liquid biopsy research assay, TruSight Oncology 500
ctDNA v2 (TSO 500 ctDNA v2), in recent months. These assays enable
labs to confidently expand oncology testing research of tissue and
liquid biopsy samples, with new transformative sequencing
economics, faster sequencing run times, and broader batch sizes on
the NovaSeq X Series for the first time.
![Illumina announced its flagship oncology products are now available on its most powerful sequencers, NovaSeq X Series, to enable comprehensive genomic profiling at greater scale and at lower overall costs for customers. Illumina announced its flagship oncology products are now available on its most powerful sequencers, NovaSeq X Series, to enable comprehensive genomic profiling at greater scale and at lower overall costs for customers.](https://mma.prnewswire.com/media/2475067/TSO_500_image_illumina.jpg)
"We are excited to deliver customers our flagship oncology
assays, now fully tested and supported on the NovaSeq X," said
Everett Cunningham, chief commercial
officer of Illumina. "Empowering labs to scale distributed
comprehensive genomic profiling serves to help advance the use of
CGP in clinical oncology research and drive precision oncology
forward."
Comprehensive genomic profiling (CGP) assesses hundreds of genes
across all variant classes, and immuno-oncology biomarkers, in a
single assay from one sample to enable therapy selection research.
CGP is increasingly included in recommended professional guidelines
in oncology.
TSO 500 HT on the NovaSeq X Series offers increased throughput
with impactful sequencing economic improvements, as compared to the
NovaSeq 6000 System. Illumina announced today that it will expand
TSO 500 HT to the company's benchtop NextSeq 1000 and NextSeq 2000
Systems later this quarter.
TSO 500 ctDNA v2 on the NovaSeq X Series enables a faster, more
sensitive, and streamlined liquid biopsy CGP workflow from
minimally invasive blood samples for solid tumor therapy selection
research, now in a fully supported and verified workflow.
Laura Knight, global VP of
Genomic Services at Almac Diagnostic Services, said: "As a leader
in next-generation sequencing diagnostics and research, Almac is
delighted that Illumina TSO 500 ctDNAv2 is now being made available
on the NovaSeq X Plus platform to enable comprehensive genomic
profiling. The NovaSeq X Plus compatibility takes molecular
analysis of blood-based biomarkers to new levels."
TSO 500 ctDNA v2 offers improvements including
transformative sequencing economics; faster sequencing run
times by about 40%, resulting in a three-day total assay turnaround
time; and more sustainable logistics, with ambient temperature
shipping for consumables.
"With increased throughput, faster turnaround time, and
optimized reagent economics, Almac can now accelerate oncology
research and diagnostic development," Knight added. "We believe
that the TSO500 ctDNA v2 assay, combined with the power of NovaSeq
X Plus, represents a transformative advancement in precision
medicine."
About the TruSight Oncology 500 portfolio
The TSO 500 portfolio is a research-use-only pan-cancer
portfolio that enables comprehensive genomic profiling from either
tissue or liquid (blood) biopsies. Designed to identify known and
emerging tumor biomarkers across 523 genes, the TSO 500 portfolio
utilizes both DNA and RNA (DNA only for liquid biopsy analysis)
from tumor samples to identify key variants critical for cancer
development and progression, such as small DNA variants (single
nucleotide variants, indels), fusions, splice variants, and copy
number variants. In addition, it assesses key genomic signatures,
such as tumor mutational burden (TMB), microsatellite instability
(MSI), and Homologous recombination deficiency (HRD).
Use of forward-looking statements
This release may contain forward-looking statements that involve
risks and uncertainties. Among the important factors to which our
business is subject that could cause actual results to differ
materially from those in any forward-looking statements are: (i)
challenges inherent in developing, manufacturing, and launching new
products and services; (ii) customer uptake of, and satisfaction
with, new products and services; and (iii) legislative, regulatory
and economic developments, together with other factors detailed in
our filings with the Securities and Exchange Commission, including
our most recent filings on Forms 10-K and 10-Q, or in information
disclosed in public conference calls, the date and time of which
are released beforehand. We undertake no obligation, and do not
intend, to update these forward-looking statements, to review or
confirm analysts' expectations, or to provide interim reports or
updates on the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as a global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical, and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture, and other emerging segments. To
learn more, visit illumina.com and connect with us on X, Facebook,
LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Salli Schwartz
858-291-6421
IR@illumina.com
Media:
Samantha Beal
PR@illumina.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/illumina-launches-new-oncology-menu-for-novaseq-x-series-customers-302214084.html
SOURCE Illumina, Inc.